ABSTRACT
The present study was undertaken to determine serum adiponectin level in patients
with cerebral infarction and to further analyze any difference in serum adiponectin
levels among atherosclerotic disorders. One hundred fifty-two subjects with atherosclerotic
disorders were enrolled, 110 males and 42 females, with the age of 67.0 ± 9.9 years (mean ± SD). They were divided
into 62 patients with cerebral infarction, 48 patients with ischemic heart disease,
and 42 patients with arteriosclerosis obliterans. Thirty-two subjects matched by age,
gender, and body mass index served as controls. Serum adiponectin levels were 7.2
± 0.6 μg/mL (mean ± SE) in the patients with cerebral infarction, 7.2 ± 0.8 μg/mL in those with ischemic heart disease, and 6.9 ± 0.9 μg/mL in those with arteriosclerosis obliterans. They were significantly less than
the level of 12.6 ± 1.9 μg/mL in the control group (P < 0.01). However, there was no difference in serum adiponectin level among three
groups of atherosclerotic disorders. In the patients with acute cerebral infarction,
serum adiponectin level was temporarily reduced from 7.3 ± 0.9 to 6.2 ± 0.8 μg/mL 14 days after the hospitalization (P < 0.01), followed by recovery to the basal value. The present findings indicate that
serum adiponectin levels are equivalently reduced in patients with atherosclerotic
disorders, and that serum adiponectin is changeable under acute phase of cerebral
infarction.
KEY INDEXING TERMS
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to The American Journal of the Medical SciencesAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Analysis of an expression profile of genes in the human adipose tissue.Gene. 1997; 190: 227-235
- Regulation of adipocyte gene expression in differentiation and syndromes of obesity/diabetes.J Biol Chem. 1993; 268: 6823-6826
- Positional cloning of the mouse obese gene and its human homologue.Nature. 1994; 372: 425-432
- Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity.Nat Med. 1996; 2: 800-803
- Increased plasma HB-EGF associated with obesity and coronary artery disease.Biochem Biophys Res Commun. 2002; 292: 781-786
- Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance.Science. 1993; 259: 87-91
- cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1).Biochem Biophys Res Commun. 1996; 221: 286-289
- Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity.Biochem Biophys Res Commun. 1999; 257: 79-83
- Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein.Diabetes. 2002; 51: 2734-2741
- Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin.Circulation. 1999; 100: 2473-2476
- Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients.Arterioscler Thromb Vasc Biol. 2000; 20: 1595-1599
- Coronary artery disease. Association of hypoadiponectinemia with coronary artery disease in men.Arterioscler Thromb Vasc Biol. 2003; 23: 85-89
- Plasma adiponectin levels and risk of myocardial infarction in men.JAMA. 2004; 291: 1730-1737
- Close association of hypoadiponectinemia with arteriosclerosis obliterans and ischemic heart disease.Metabolism. 2005; 54: 653-656
- Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway.Circulation. 2000; 102: 1296-1301
- Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages.Circulation. 2001; 103: 1057-1063
- Adiponectin stimulates production of nitric oxide in vascular endothelial cells.J Biol Chem. 2003; 278: 45021-45026
- Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells.J Biol Chem. 2004; 279: 1304-1309
- Hypoadiponectinemia is associated with ischemic cerebrovascular disease.Arterioscler Thromb Vasc Biol. 2005; 25: 821-826
- Plasma adiponectin levels and five-year survival after first-ever ischemic stroke.Stroke. 2005; 36: 1915-1919
- An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls.Horm Metab Res. 2000; 32: 47-50
- Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell.Circulation. 2002; 105: 2893-2898
- Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages.Blood. 2000; 96: 1723-1732
- Role of adiponectin in preventing vascular stenosis: the missing link of adipo-vascular axis.J Biol Chem. 2002; 277: 37487-37491
- Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia.J Clin Endocrinol Metab. 2001; 86: 1930-1935
- Adiponectin and the development of type 2 diabetes: the atherosclerosis risk in communities study.Diabetes. 2004; 53: 2473-2478
- Young men with high-normal blood pressure have lower serum adiponectin, smaller LDL size, and higher elevated heart rate than those with optimal blood pressure.Diabetes Care. 2002; 25: 971-976
- Hypoadiponectinemia is an independent risk factor for hypertension.Hypertension. 2004; 43: 1318-1323
- Decreased plasma adiponectin concentration in patients with essential hypertension.Am J Hypertens. 2003; 16: 72-75
Article info
Publication history
Accepted:
September 22,
2006
Received:
May 12,
2006
Identification
Copyright
© 2007 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights reserved.
